Share on StockTwits
 

Celgene Corp. (NASDAQ:CELG) is scheduled to be posting its quarterly earnings results on Thursday, January 30th. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Celgene Corp. (NASDAQ:CELG) opened at 159.98 on Wednesday. Celgene Corp. has a 52 week low of $96.78 and a 52 week high of $174.66. The stock’s 50-day moving average is $166.3 and its 200-day moving average is $153.0. The company has a market cap of $65.923 billion and a price-to-earnings ratio of 45.00.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank raised their price target on shares of Celgene Corp. from $170.00 to $190.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. On the ratings front, analysts at TheStreet reiterated a “buy” rating on shares of Celgene Corp. in a research note to investors on Friday, January 17th. Finally, analysts at Leerink Swann raised their price target on shares of Celgene Corp. from $177.00 to $197.00 in a research note to investors on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company’s stock. Celgene Corp. presently has an average rating of “Buy” and a consensus price target of $175.36.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.